Key result
Dexmedetomidine reduces perioperative myocardial ischemia and arrhythmias but increases bradycardia.
Why the study?
The effects of dexmedetomidine on perioperative cardiac adverse events in elderly patients with coronary heart disease were not well established.
Does dexmedetomidine reduce perioperative cardiac adverse events and biomarker elevation in elderly patients with coronary heart disease undergoing gastric cancer surgery?
RCT (n=60)
randomly divided
Does dexmedetomidine reduce perioperative cardiac adverse events and biomarker elevation in elderly patients with coronary heart disease undergoing gastric cancer surgery?
p-value: p=<0.05
Dexmedetomidine administration before anesthesia induction in elderly patients with coronary heart disease undergoing non-cardiac surgery may reduce perioperative myocardial injury and ischemic events, despite an increased risk of intraoperative bradycardia.
Supports dexmedetomidine before induction in elderly CHD noncardiac surgery despite bradycardia risk; extends RCT evidence to gastric cancer resection.
OBJECTIVE: To investigate the effects of dexmedetomidine on perioperative cardiac adverse events in elderly patients with coronary heart disease. Methods: Sixty elderly patients, who were diagnosed as coronary heart disease and underwent gastric cancer operation, were randomly divided into 2 groups (n=30): the dexmedetomidine group (Dex group) and the control group. In the Dex group, dexmedetomidine was administered intravenously at 0.5 μg/(kg·h) after a bolus infusion at 0.5 μg/kg for 10 min before anesthesia induction. In the control group, equal volume of normal saline was infused instead of dexmedetomidine. The 2 groups received the same anesthesia treatment. The venous bloods were collected at the preoperative 0 h and postoperative 24 h. The concentrations of cardiac troponin (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP) and hypersensitive C-reactive protein (hs-CRP) were determined. The ECG was monitored at the above time and the postoperative incidence of cardiac adverse events was recorded. Results: The levels of cTnI, NT-proBNP and hs-CRP in serum were elevated in the 2 groups after the operation. Compared with the control group, the levels of cTnI, NT-proBNP and hs-CRP were significantly decreased in the Dex group (P<0.05). Compared with the control group, the incidence of bradycardia were significantly increased, while the myocardial ischemia and tachycardia were significantly decreased in the Dex group during the operation (P<0.05); the incidence of silent myocardial ischemia and arrhythmia was significantly reduced at 3 days after operation in the Dex group (P<0.05). Conclusion: Dexmedetomidine could decrease the incidence of cardiac adverse events in elderly patients with coronary heart disease.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2017) conducted an RCT in coronary heart disease undergoing gastric cancer operation (n=60). Dexmedetomidine vs. Normal saline was evaluated on Perioperative cardiac adverse events and cardiac biomarker levels (p=<0.05). Dexmedetomidine significantly reduced perioperative myocardial ischemia, tachycardia, and postoperative arrhythmias, and lowered cardiac biomarkers, but increased bradycardia (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: